Zydus Life Share Price, Stock Analysis & Company Profile
Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) is a global, research-driven pharmaceutical company that spans the entire value chain from drug discovery to delivery. As a key player in the Pharmaceuticals & Drugs sector, Zydus has established a significant presence in India, the United States, and emerging markets, providing high-quality healthcare solutions for over seven decades.
This page serves as a comprehensive portal for investors to monitor the Zydus Life share price, conduct an in-depth Zydus Life stock analysis, and evaluate the company’s extensive global operations and research pipeline.
About Zydus Lifesciences Limited
Founded in 1952 by Mr. Ramanbhai B. Patel, Zydus Lifesciences is headquartered in Ahmedabad and has grown into one of India’s leading pharmaceutical companies. The company underwent a major rebranding in 2022 to "Zydus Lifesciences" to reflect its shift towards life sciences and innovative healthcare.
Zydus is renowned for its diverse portfolio, which includes generic drugs, specialty formulations, vaccines, biosimilars, and active pharmaceutical ingredients (APIs). The company made global headlines as the developer of ZyCoV-D, the world’s first DNA-based vaccine for COVID-19.
Zydus Lifesciences Business Model
The company operates an integrated and research-led business model designed to cater to both regulated and emerging markets. Key pillars of its operations include:
-
North America Business: The largest revenue contributor (approx. 41%), focusing on a strengthening specialty portfolio and new product launches (ANDAs).
-
India Formulations: A solid domestic business with a strong shift towards the chronic portfolio, which now accounts for over 45% of India's revenue.
-
Consumer Wellness: Operating through Zydus Wellness, the company manages iconic household brands like Sugar Free, Glucon-D, and Nycil.
-
Biologics and Biosimilars: A fast-growing segment focusing on complex biological therapies for autoimmune diseases and oncology.
-
Global Emerging Markets: Broad-based growth across Europe and emerging markets, often exceeding 20% growth near term.
Zydus Lifesciences IPO and Listing Details
Zydus Lifesciences has been a long-standing constituent of the Indian capital markets, providing significant value to its early investors through consistent growth.
- Listing Year: 2000
- IPO Price: Rs 250 per share (Unadjusted)
- Listing Price: Rs 196.90 per share
- Face Value: Rs 1 per share (Post-split)
- ISIN: INE010B01027
- NSE Symbol: ZYDUSLIFE
- BSE Scrip Code: 532321
Zydus Lifesciences Corporate Action History
The company has a consistent history of rewarding shareholders through bonuses, dividends, and stock splits, reflecting its stable financial health.
Bonus Share History
Zydus Lifesciences has issued bonus shares to capitalise its reserves and reward its long-term equity partners.
Stock Split History
The company has split its shares in the past to improve liquidity and make them more accessible to retail investors.
Dividend History
The company follows a consistent dividend policy, declaring payouts annually based on its net profit performance.
-
FY 2025-26: Declared a final dividend of Rs 11.00 per share (announced May 2025; Record date July 2025).
-
FY 2024-25: Declared a final dividend of Rs 3.00 per share.
-
FY 2023-24: Declared a final dividend of Rs 6.00 per share.
Investor Resources Available on This Page
Retail investors can find a variety of tools in the respective tables on this page to conduct a professional Zydus Life stock analysis:
-
Price Chart: Monitor the historical performance and price trends of the Zydus Lifesciences share price. (data delayed by 15 minutes)
-
Company Ratios: Review critical financial indicators like P/E ratio, Price-to-Book, ROCE, and Debt-to-Equity.
-
Quarterly Results: Track the company’s performance across domestic and international markets every quarter.
-
Balance Sheet: Analyse the company's capital structure, investment in R&D, and its asset base.
-
Cash Flow Statement: Evaluate the company’s ability to generate cash from its massive global operations.
-
Shareholding & Promoters: Check the stake held by the Patel family (Promoters) and institutional investors.
-
Pros & Cons: A simplified summary of the company’s R&D strengths versus regulatory risks in international markets.
-
Annual Reports: Download official documents for deep dives into management’s strategy and product pipelines.
Frequently Asked Questions (FAQs)
Q1. What is the latest Zydus Lifesciences share price?
The current price is displayed at the top of this page. Please note that all price data and charts are subject to a 15-minute delay from the exchanges.
Q2. Who owns Zydus Lifesciences?
Zydus Lifesciences is promoted by the Patel family, led by Chairman Pankaj R. Patel and Managing Director Dr. Sharvil Patel.
Q3. When was the last stock split for Zydus Lifesciences?
The last stock split for the company took place in October 2015, when the face value was reduced from Rs 5 to Rs 1 per share.
Q4. Does Zydus Lifesciences pay regular dividends?
Yes, the company has a strong track record of paying regular annual dividends. The specific dividend amount is typically declared after the board reviews the annual financial results.
Q5. What is the difference between Cadila Healthcare and Zydus Lifesciences?
They are the same company. The name was officially changed from Cadila Healthcare Limited to Zydus Lifesciences Limited in early 2022 to better represent its global identity.
Q6. Where can I find the latest quarterly results of Zydus Life?
All quarterly financial updates, including consolidated revenue and net profit figures, are available in the "Quarterly Results" table on this page.
Q7. How can I download the Zydus Life Annual Report?
You can access and download the latest as well as past Annual Reports from the "Reports" or "Documents" section table provided on this page.